BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 30469352)

  • 1. Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy.
    Jo Y; Kim EH; Sai S; Kim JS; Cho JM; Kim H; Baek JH; Kim JY; Hwang SG; Yoon M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30469352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
    Stupp R; Taillibert S; Kanner AA; Kesari S; Steinberg DM; Toms SA; Taylor LP; Lieberman F; Silvani A; Fink KL; Barnett GH; Zhu JJ; Henson JW; Engelhard HH; Chen TC; Tran DD; Sroubek J; Tran ND; Hottinger AF; Landolfi J; Desai R; Caroli M; Kew Y; Honnorat J; Idbaih A; Kirson ED; Weinberg U; Palti Y; Hegi ME; Ram Z
    JAMA; 2015 Dec; 314(23):2535-43. PubMed ID: 26670971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields).
    Shteingauz A; Porat Y; Voloshin T; Schneiderman RS; Munster M; Zeevi E; Kaynan N; Gotlib K; Giladi M; Kirson ED; Weinberg U; Kinzel A; Palti Y
    Cell Death Dis; 2018 Oct; 9(11):1074. PubMed ID: 30341282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
    Kesari S; Ram Z;
    CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?
    Ornelas AS; Porter AB; Sharma A; Knox MG; Marks LA; Wingerchuk DM; O'Carroll CB
    Neurologist; 2019 Mar; 24(2):71-73. PubMed ID: 30817495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial.
    Guberina N; Pöttgen C; Kebir S; Lazaridis L; Scharmberg C; Lübcke W; Niessen M; Guberina M; Scheffler B; Jendrossek V; Jabbarli R; Pierscianek D; Sure U; Schmidt T; Oster C; Hau P; Grosu AL; Stuschke M; Glas M; Nour Y; Lüdemann L
    Radiat Oncol; 2020 Apr; 15(1):83. PubMed ID: 32307022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the efficacy of tumor electric field therapy against glioblastoma: An in vivo and in vitro study.
    Wu H; Yang L; Liu H; Zhou D; Chen D; Zheng X; Yang H; Li C; Chang J; Wu A; Wang Z; Ren N; Lv S; Liu Y; Jia M; Lu J; Liu H; Sun G; Liu Z; Liu J; Chen L
    CNS Neurosci Ther; 2021 Dec; 27(12):1587-1604. PubMed ID: 34710276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.
    Kim CY; Paek SH; Nam DH; Chang JH; Hong YK; Kim JH; Kim OL; Kim SH
    J Neurooncol; 2020 Feb; 146(3):399-406. PubMed ID: 32020470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
    Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z
    JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-Wide Expression and Anti-Proliferative Effects of Electric Field Therapy on Pediatric and Adult Brain Tumors.
    Branter J; Estevez-Cebrero M; Diksin M; Griffin M; Castellanos-Uribe M; May S; Rahman R; Grundy R; Basu S; Smith S
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T Cells Retain Pivotal Antitumoral Functions under Tumor-Treating Electric Fields.
    Diamant G; Simchony Goldman H; Gasri Plotnitsky L; Roitman M; Shiloach T; Globerson-Levin A; Eshhar Z; Haim O; Pencovich N; Grossman R; Ram Z; Volovitz I
    J Immunol; 2021 Jul; 207(2):709-719. PubMed ID: 34215656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib increases tumor treating fields-induced cell death in glioblastoma by inhibiting STAT3.
    Kim JY; Jo Y; Oh HK; Kim EH
    Am J Cancer Res; 2020; 10(10):3475-3486. PubMed ID: 33163284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields.
    Chang E; Pohling C; Beygui N; Patel CB; Rosenberg J; Ha DH; Gambhir SS
    J Neurooncol; 2017 Sep; 134(2):259-268. PubMed ID: 28681243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress and prospect in tumor treating fields treatment of glioblastoma.
    Liu S; Shi W; Zhao Q; Zheng Z; Liu Z; Meng L; Dong L; Jiang X
    Biomed Pharmacother; 2021 Sep; 141():111810. PubMed ID: 34214730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-treating fields as a fourth treating modality for glioblastoma: a meta-analysis.
    Magouliotis DE; Asprodini EK; Svokos KA; Tasiopoulou VS; Svokos AA; Toms SA
    Acta Neurochir (Wien); 2018 Jun; 160(6):1167-1174. PubMed ID: 29696502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling.
    Wenger C; Miranda PC; Salvador R; Thielscher A; Bomzon Z; Giladi M; Mrugala MM; Korshoej AR
    IEEE Rev Biomed Eng; 2018; 11():195-207. PubMed ID: 29993870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma.
    Riley MM; San P; Lok E; Swanson KD; Wong ET
    J Vis Exp; 2019 Apr; (146):. PubMed ID: 31058901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
    Burri SH; Gondi V; Brown PD; Mehta MP
    Am J Clin Oncol; 2018 Feb; 41(2):191-196. PubMed ID: 28832384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
    Fishman H; Monin R; Dor-On E; Kinzel A; Haber A; Giladi M; Weinberg U; Palti Y
    J Neurooncol; 2023 May; 163(1):83-94. PubMed ID: 37131108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.
    Lazaridis L; Schäfer N; Teuber-Hanselmann S; Blau T; Schmidt T; Oster C; Weller J; Tzaridis T; Pierscianek D; Keyvani K; Kleinschnitz C; Stuschke M; Scheffler B; Deuschl C; Sure U; Herrlinger U; Kebir S; Glas M
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):787-792. PubMed ID: 31828428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.